A collaborative effort between Rheumatology and Oncology offers guidance to doctors treating patients for inflammatory arthritis caused by treatment with “immune checkpoint inhibitors”, a type of cancer therapy.
A study lead by Lisa Christopher-Stine, M.D., M.P.H. identified “Hiker’s Feet” as a new skin finding in some patients with inflammatory muscle disease (myositis).
Younger patients with a specific form of myositis associated with antibodies to a protein called HMGCR have a worse prognosis than older patients.
Medical record review of patients admitted to the Johns Hopkins Hospital over 20-years, revealed that pneumocystis jiroveci pneumonia infection is a rare but persistent risk for patients with rheumatic diseases.
The study provides new evidence that a bacterium known to cause chronic inflammatory gum infections also triggers the inflammatory autoimmune response characteristic of chronic, joint-destroying rheumatoid arthritis (RA). The new findings have important implications for prevention and treatment of RA.
A new biomarker discovered using cutting-edge technologies is found in people who develop scleroderma and cancer within a short period of time.
